

COLIN HASLAM, TORD ANDERSSON,  
NICK TSITSIANIS AND YA PING YIN

# REDEFINING BUSINESS MODELS

STRATEGIES FOR A  
FINANCIALIZED WORLD



ROUTLEDGE



# REDEFINING BUSINESS MODELS

Strategies for a  
financialized world

*Colin Haslam, Tord Andersson,  
Nick Tsitsianis and Ya Ping Yin*



Routledge  
Taylor & Francis Group

LONDON AND NEW YORK

First published 2013  
by Routledge  
2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN

Simultaneously published in the USA and Canada  
by Routledge  
711 Third Avenue, New York, NY 10017

*Routledge is an imprint of the Taylor & Francis Group, an informa business*

© 2013 Colin Haslam, Tord Andersson, Nick Tsitsianis and Ya Ping Yin

The right of Colin Haslam, Tord Andersson, Nick Tsitsianis and Ya Ping Yin to be identified as authors of this work has been asserted by them in accordance with sections 77 and 78 of the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers.

*Trademark notice:* Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

*British Library Cataloguing in Publication Data*

A catalogue record for this book is available from the British Library

*Library of Congress Cataloging in Publication Data*

Redefining business models : strategies for a financialized world /

Colin Haslam . . . [et al.].

p. cm.

Includes bibliographical references and index.

1. Business enterprise—Finance. 2. Capital—Accounting.

3. Surplus (Accounting) I. Haslam, Colin.

HG4026.R388 2012

658.15—dc23

2011052215

ISBN: 978-0-415-67440-9 (hbk)

ISBN: 978-0-415-67991-6 (pbk)

ISBN: 978-0-203-11250-2 (ebk)

Typeset in Bembo

by Swales & Willis Ltd, Exeter, Devon

# LIST OF TABLES

2.1	Exhibit for rate of return, residual income and spread	19
2.2	Johnson & Johnson: income and expenses by function	22
2.3	Johnson & Johnson: income and expenses by nature	24
2.4	Johnson & Johnson: VAR in sales and share	25
2.5	Johnson & Johnson: employment costs in sales and value retained	25
2.6	Johnson & Johnson: distribution of EBITDA	26
2.7	Johnson & Johnson: ROCE	26
2.8	Pooling versus market value absorption	27
3.1	Tangible and intangible investments by UK firms	35
3.2	Merck: implicit holding gains from cash invested in treasury stock	37
3.3	Extracts from Apple Inc.'s balance sheet and cash flow statement, 2010	38
3.4	Institutional investors: funds under management	41
3.5	Tesco plc directors' remuneration and bonuses	43
3.6	Johnson & Johnson: cost structure and return on capital	47
3.7	Johnson & Johnson: balance sheet asset structure	47
4.1	Information content within the econosphere	56
4.2	Adobe treasury stock, 31 March 2005	59
4.3	Royal Bank of Scotland: income statement, December 2008	62
4.4	Pfizer and Apple: cash application, 1990–2010	65
5.1	Population growth (in millions)	79
5.2	Manufacturing labour costs per hour in the USA, China and India	80
5.3	G7: real GDP per capita, 1980–2010	81
5.4	USA: nominal and real GDP growth rates	82
5.5	USA: all private industry: median real earnings and employment index	83
5.6	Shares of global imports and exports of capital	85

5.7	Central government finances	86
5.8	Investment in GDP	87
5.9	Size of the capital markets, 2009	94
5.10	Securitization in Europe and the USA, 2000–2011	98
5.11	Securitization balances and credit ratings, 2008 and 2011	98
6.1	US Household key assets and liability balance sheet structure	110
6.2	S&P 500 firms' pension and other post-employment benefit (OPEB) funding status	114
6.3	Global merger and acquisitions and market to book multiples, 1990–2010	115
6.4	S&P 500 treasury stock at cost and market value, April 2007	118
6.5	US real estate and consumer loans charged off in total loans outstanding	121
6.6	Eurozone government deficits and borrowing as a per cent of GDP	123
7.1	Business combination schematic	137
7.2	Key financial operating ratios and earnings capacity	142
7.3	Labour costs: USA, Europe, Asia-Pacific, Latin America and the rest of the world	143
7.4	Molex cost structure as per cent of total sales for 2000 and 2008	147
7.5	US computer and electronic industry cash surplus margin (parent and foreign affiliates)	148
8.1	US annual securitization issuances, 1996–2010	157
8.2	US securitizations: balances outstanding and credit rating	157
8.3	US household mortgage foreclosures	161
8.4	Wachovia: loans, credit losses and net income, Q3 2007 to Q3 2008	165
8.5	Wachovia: market value, Q3 2007 to Q3 2008	166
8.6	Wachovia: net loss after goodwill impairment	167
8.7	Extract from Wells Fargo S-4 purchase cost of Wachovia	168
9.1	Private equity leverage model	176
9.2	EMI financials, 2000–2007	181
9.3	EMI financials after the Terra Firma buy-out	182
9.4	EMI balance sheet, 2007–2010	182
9.5	Terra Firma equity investment and market value at year end	184
9.6	Profit and loss account, Terra Firma, 2008 and 2009	185
9.7	Terra Firm balance sheet summary, 2009 and 2008	186
10.1	Major markets for pharmaceutical products	191
10.2	US big-pharma financial profiles	192
11.1	Worldwide personal computers in use, 1975–2020	205
11.2	Nominal sales growth rates in S&P 500 and S&P 500 DLBM	215
12.1	Top twenty-five hospices' income breakdown	221
12.2	Income breakdown: Pilgrims Hospice	221

## ABOUT THE AUTHORS

**Colin Haslam** is Professor of Finance and Accounting and Director of the Finance Accounting Research Unit (FARU) at the Business School of the University of Hertfordshire. His research interests span both the public and private sector. He has published a number of reports including *Off-shoring of City Jobs* and *New Technology Firms on the Alternative Investment Market (AIM)* and, most recently, he was joint author of *UK Bio-pharma: Innovation, Re-invention and Capital at Risk* for the Institute of Chartered Accountants Scotland (ICAS). Colin has acted as chair of the Business and Management panel for the Academy of Finland Research Council and is a member of the European Financial Reporting Advisory Group (EFRAG) 'Disclosure Framework Advisory Panel', the aim of which project is to improve the disclosure of information in the notes to corporate financial statements.

**Tord Andersson** runs a management consulting business in Sweden and is a business broker for small and medium enterprises within Swedbank Företagsförmedling. He is also a visiting Senior Lecturer in Finance and an active researcher in the Finance Accounting Research Unit (FARU) at the Business School, University of Hertfordshire. Tord's research interests are concerned with corporate sector and firm-level performance for sustainable wealth accumulation, and with advancing accounting frameworks of analysis within the field of corporate strategy and corporate finance. Previously he worked in the telecommunications industry as product manager before moving into the finance sector as sell-side financial analyst (CEFA/AFA) and then subsequently a buy-side senior investment analyst. He is a member of the Swedish Society of Financial Analysts (SFF) and XBRL Sweden.

**Nick Tsitsianis** is a Principal Lecturer at the University of Hertfordshire and an active researcher in its Finance Accounting Research Unit (FARU). Prior to joining the university he was a lecturer at Brunel and Kent universities. His specialist

research involves the construction of large-scale panel datasets applied to a range of research fields: reference values for gauging income and happiness across Europe, identifying the adopters and non-adopters of broadband, and tracking corporate performance in the S&P 500 and other major stock market indices. Nick has published on corporate financial performance and is joint author of the report *UK Bio-pharma: Innovation, Reinvention and Capital at Risk* for the Institute of Chartered Accountants Scotland (ICAS).

**Ya Ping Yin** is a Senior Lecturer in Economics in the Business School of the University of Hertfordshire. He was educated as a national economic planner and specialist in national accounting systems in Beijing and was subsequently appointed as an economic systems modeller at Strathclyde University. Dr Yin's main research interests are focused on how we account for productivity and efficiency measurement; market conditions, firm conduct and performance; and multi-sectoral growth models. His recent research cautioned readers about the nature and risk of accumulating consumer debt and questioned the sustainability of a banking-led economic growth trajectory. His published research highlights the structural fragility and increased level of systemic risk generated within the UK national business model.

# ACKNOWLEDGEMENTS

This book could not have been written without the support of a number of others and we would like to acknowledge these contributions.

First of all, we would like to thank Jacqueline Curthoys, editor at Routledge, for her initial supportive response, and the anonymous reviewers she commissioned, who took the time and care to respond constructively and critically to our initial proposals.

We are grateful for the support of the University of Hertfordshire Business School, its dean (Julie Newlan and then Jerry Forrester) and its research director, Keith Randle, for providing resources to access datasets, and also the precious resource of 'time' allocated to this team so that they could deliver this project over such a short period. We also wish to express our gratitude to other members of the research team who are not co-authors but have in their different ways helped to make this book possible by their support, by covering for us and by helping to gather data and evidence: George Katechos, Grigorios Theodosopoulou and Edward Lee, who has been a joint author on a number of previous articles and whose ideas have helped shape material included in this text.

Our thanks also go to the Institute of Chartered Accountants Scotland (ICAS), for its funding of a research project on SME bio-pharma which helped to inform Chapter 10, and to the European Financial Advisory Reporting Group for their observations about the nature of business models and responses in discussion.

Finally, we wish to thank our families who have given their support and encouragement to finish the project we had all started.



# ABBREVIATIONS

AIDS	acquired immunodeficiency syndrome
AIG	American International Group
AIM	Alternative Investment Market
ARM	adjustable rate mortgages
BEA	Bureau of Economic Analysis (USA)
BICRA	Banking Industry Country Risk Assessment
BM	business model
CAGR	compound annual growth rate
Cash ROCE	EBITDA as percentage of capital employed, where capital employed is the sum of equity and long-term debt
CDS	credit default swaps
CEO	chief executive officer
CFA	chartered financial analysts
CFROI	cash flow return on investment
CIBER	Centre for International Business Education and Research
CII	capital intensity index
DLBM	digital lifestyle business model
EBIT	earnings before interest and tax
EBITDA	earnings before interest, tax, depreciation and amortization
EPS	earnings per share
EVA <sup>TM</sup>	Economic Value Added
FASB	Financial Accounting Standard Board
FDA	Food and Drugs Administration Agency
FDI	foreign direct investment
FDIC	Federal Deposit Insurance Corporation
FVA	fair value accounting
GAAP	Generally Accepted Accounting Practice

GDP	gross domestic product
GIIPS	Greece, Ireland, Italy, Portugal and Spain
GO	gross output
GOS	gross operating surplus
GSK	GlaxoSmithKline
GVA	gross value added
IAS	International Accounting Standards
IASB	International Accounting Standards Board
IBM	International Business Machines
IC	intermediate consumption
IFRS	International Financial Reporting Standards
IMF	International Monetary Fund
IRR	internal rate of return
LBO	leveraged buy-out
LC	labour costs
MKTVAL	market value at year end
MVA	market value added
NCE	new chemical entities
NETINCPS	net income per share
NOPAT	net operating profit after tax
NPV	net present value
OPEB	other post-employment benefits
OTC	over the counter
PEBM	private equity business model
PEP	private equity partnership
R&D	research and development
RBS	Royal Bank of Scotland
RBT	resource-based theory
ROA	return on assets
ROCE	return on capital employed
ROE	return on equity
ROI	return on investment
S&P	Standard and Poor's
SBB	share buy-backs
SFAS	Statement of Financial Accounting Standards
SME	small and medium enterprise
SPV	special purpose vehicle
SORP	Statement of Recommended Practice
TIPS	Treasury Inflation-Protected Securities
VAR	value added retained
VC	venture capital
WACC	weighted average cost of capital

# CONTENTS

<i>List of figures</i>	<i>vi</i>
<i>List of tables</i>	<i>x</i>
<i>About the authors</i>	<i>xii</i>
<i>Acknowledgements</i>	<i>xiv</i>
<i>Abbreviations</i>	<i>xv</i>
1 Introduction	1
2 Accounting for the firm as a business model	11
3 Strategy: arbitrage for financial leverage	31
4 Business models: reworked for a financialized world	51
5 Business models: global context	77
6 Accounting for national business models	103
7 Business models: adaptation and restructuring	130
8 US banking: a viable business model?	151
9 The private equity business model: leveraged and fragile	172
10 Bio-pharma: a maturing business model?	188
11 Business models for a digital lifestyle	204
12 Accounting for the UK hospice business model	219
<i>Notes</i>	<i>226</i>
<i>References</i>	<i>229</i>
<i>Index</i>	<i>240</i>

# LIST OF FIGURES

2.1	DuPont pyramid of ratios (after Chandler, 1977)	20
2.2	US and European bank assets as reported and under IFRS	28
2.3	US/European bank equity to risk adjusted assets	29
3.1	S&P 500 dividends and share buybacks as % of cash (EBITDA)	36
3.2	Institutional investors: assets allocations	41
3.3	US equity holdings: households and institutions	42
3.4	Investment in GDP: advanced economics	45
3.5	S&P 500 capital expenditure and cash to shareholders	46
3.6	Stakeholder interactions	49
4.1	Business model within the econosphere	56
4.2	The focal firm in a business model	58
4.3	Financial purpose of a focal firm in its business model	58
4.4	US S&P 500 market value and goodwill to equity exposure	61
4.5	Pfizer: cash margin and cash ROCE	64
4.6	Apple Inc.: cash margin and cash ROCE	64
4.7	Apple Inc. and DLBM: cash margin	66
4.8	Apple Inc. and DLBM: capital intensity (CII)	67
4.9	Apple Inc. and DLBM: cash ROCE	67
4.10	Pfizer relative to big-pharma business model: cash margin	68
4.11	Pfizer relative to big-pharma business model: capital intensity	68
4.12	Pfizer relative to big-pharma business model: cash ROCE	69
4.13	Business model financial typology	70
4.14	S&P 500 food and staples: cash margin	71
4.15	S&P 500 food and staples: capital intensity and cash ROCE	71
4.16	S&P 500 real estate business model	72
4.17	US biotech business model	73
4.18	Share of big-pharma market value	74

4.19	Share of DLBM market value: Apple, Microsoft, IBM, Intel and Cisco	75
5.1	Economically active population	80
5.2	GDP: G7, India and China	81
5.3	Share of global GDP	82
5.4	USA: all private industry: median real earnings and employment index	83
5.5	G7, China and India: share of global FDI flows	84
5.6	G7 and China/India: trade balances	85
5.7	Long-term interest rates, 1960–2010	87
5.8	Intermediate costs in gross output	89
5.9	Labour costs in gross output	90
5.10	Operating surplus as a percentage of gross output in the advanced economies	90
5.11	Europe: intermediate, labour costs and gross operating surplus for the fifteen members of the European Union	91
5.12	Global capitalization and capitalization to GDP ratio	93
5.13	US GDP and capitalization, 1950–2010	94
5.14	US household equity and pension funds	95
5.15	Securitization	97
5.16	Announced merger and acquisitions worldwide, 1985–2010	99
5.17	Global real estate value relative to world GDP	101
6.1	Germany: GOS in GO	104
6.2	UK: GOS in GO	105
6.3	USA: GOS in GO	105
6.4	German institutional sectors: GOS as % of debt and equity	106
6.5	UK institutional sectors: GOS as % of debt and equity	107
6.6	US institutional sectors: GOS as % of debt and equity	107
6.7	Japanese institutional sectors: GOS as % of debt and equity	108
6.8	Household real estate, financial assets and loans outstanding to disposal income (ratio)	109
6.9	Case Shiller Composite-10 US house price index	110
6.10	UK mortgage equity as % of individual post-tax income	112
6.11	USA, Europe and Japan: stock market values	113
6.12	S&P 500 goodwill as % of equity, 1990–2008	116
6.13	S&P 500 dividends and SBBs out of profits	118
6.14	US banks: leveraging return on assets	120
6.15	Long-term interest rates, Greece and euro area, 2008–2011 Q3	123
6.16	US government and agency debt	125
7.1	Announced mergers and acquisitions worldwide, 1985–2010	131
7.2	Announced mergers and acquisitions in the USA, 1985–2010	131
7.3	S&P 500 market value index, 1990–2011	133
7.4	S&P 500 price to book value, 1990–2009	134
7.5	S&P 500 cash margin and cash ROCE	136
7.6	Pfizer cash ROCE and goodwill to equity	138

7.7	US goods-producing firms: value retention rate in sales	144
7.8	US parent and foreign affiliate labour costs in sales	145
7.9	US industry parent and foreign affiliate cash margin in sales	145
7.10	US parent and affiliate CFROA	146
7.11	Molex Inc.: key financial ratios, 1990–2010	147
7.12	Molex cash ROCE and market value	149
8.1	US financial sector share of GDP and employment	153
8.2	US finance sector cost structure	153
8.3	US banking sector net income on assets	154
8.4	US banks' equity to assets	158
8.5	US mortgages outstanding and GDP nominal growth, 1950–2010	159
8.6	FDIC-insured institutions' net loans charge-off rates	161
8.7	FDIC-insured banks: pre-tax income and provision for losses	162
8.8	US banks' S&P 500 market value index, 2002–2011	163
9.1	Accumulated global private equity funds raised, 1999–2011	174
9.2	Global private equity called funds and distributed funds	177
9.3	Equity contribution to private equity leveraged buy-outs, 2000–2010	178
9.4	Private equity funds' IRR by fund vintage, 1990–2008	179
10.1	Drug testing process	190
10.2	US S&P 500 pharma business model cash margin	192
10.3	US S&P 500 big-pharma and biotech business model sales revenue	193
10.4	Pfizer Inc.: financial profile, 2001	196
10.5	Pfizer Inc.: financial profile, 2009	196
10.6	US big-pharma cash ROCE	197
10.7	US big-pharma share of S&P 500 market value and cash ROCE	197
10.8	Biotech sales and market value relative to big-pharma	198
10.9	US S&P 500 biotech and big-pharma cash ROCE	198
10.10	The SME bio-pharma business model	201
10.11	The number of bio-pharma SMEs listed on London AIM	202
10.12	AIM SME bio-pharma total investment	202
11.1	Mobile phone subscribers worldwide	205
11.2	DLBM focal firms' cash margin	209
11.3	DLBM focal firms' cash ROCE	209
11.4	DLBM focal firms' market value to sales ratio	210
11.5	Intel, financial profile, 2009	210
11.6	Microsoft, financial profile, 2009	211
11.7	Apple, financial profile, 2009	211
11.8	Evolution of sales revenue in the S&P 500 digital lifestyle business model	212
11.9	Evolution of cash generated in the S&P 500 digital lifestyle business model	212
11.10	S&P 500 DLBM cash margin and cash ROCE	214
11.11	S&P 500 DLBM market value to EBITDA ratio	214

11.12	S&P 500 DLBM sales growth and share of S&P 500 sales revenue	215
11.13	S&P 500 DLBM share of S&P 500 sales and cash (EBITDA)	216
11.14	S&P 500 DLBM share of S&P 500: sales, cash and market value	216
12.1	Top twenty-five UK hospices: income and expenditure	222
12.2	Hospice cash burn balances and investments	223

# 1

## INTRODUCTION

No quality newspaper has recently been complete without a story about the banking crisis and how sovereign governments are finding it increasingly difficult to fund their deficits and refinance their roll-over debt. The current financial crisis is global and interconnected because adjustments are transmitted and amplified by accounting systems that equalize the value of assets and liabilities either up or down. According to a recent Bank for International Settlements report *Rescue Packages and Bank Lending*, recent financial problems are related to the instability of the banking business model.

The global financial crisis is widely regarded as the worst financial crisis since the Great Depression. While financial distress afflicted the entire financial system, many crisis-related problems crystallised in the banking system, starting with the interbank market freeze in August 2007. Between early 2007 and March 2009, the stock market valuation of the banking sector declined by 79% from peak to trough, losing over 20% relative to the broader equity index (comparing the MSCI World Index and Bank sub index). CDS<sup>1</sup> premia shot up across the board, indicating that the market was pricing in a greater likelihood of bank defaults.

*(Bank for International Settlements, 2011b: 2)*

Liquidity in a credit-based system reconciles timing differences between long-lived assets (loans) and short-term liabilities (deposits). A distinction can be made between liquidity generated by central banks (official) and that which is generated by private corporate financial and non-financial sectors. Private liquidity now far exceeds 'official' liquidity and where asset values (capitalizations) inflate there is a possibility of a 'liquidity disconnect'. That is, capitalizations accelerate ahead of income and surplus driven by factors other than the trajectory of earnings/surplus.



However, when asset valuations reduce the serviceability of capital accumulated under threat, this can compromise the solvency of business models amplifying asset price adjustments, especially where a substantial proportion of ‘realizable collateral’ is imaginary and based upon intangible goodwill and optimistic assumptions about counterparty viability.

A Bank of England *Financial Stability Report* (December 2011) observes that ‘A flight to safety could cause sharp asset price movements . . . Shifts in capital flows as investors seek “safe havens” could cause large and disruptive movements in many asset prices’ (Bank of England, 2011: 18). The banking crisis of 2007–2009 reveals how credit losses (loan defaults) were quickly followed by goodwill write-downs that rapidly undermined banking sector capital adequacy, triggering the need for official interventions to sustain balance sheets, capital adequacy and solvency.

As the crisis proceeded, total credit losses eventually outpaced recapitalizations. Combined credit losses of \$1,508 billion (\$801 billion in North America) exceeded total recapitalizations of \$1,318 billion (\$515 billion in North America).

(*Bank for International Settlements, 2011b: 4*)

Banks also increasingly came under capital pressure. The IMF estimates that banks’ worldwide credit-related write-downs were around \$1.6 trillion between mid-2007 and end-2009. The national banking systems that have tended to cut back lending relatively sharply were the ones that have received the largest capital injections from their governments – a proxy for the pressure on their capital positions.

(*Bank of England, 2010: 7*)

Thus in a credit-based system there is an ongoing tension between cash surplus capacity (liquidity) and ongoing capitalizations (as wealth accumulation for households) where complex global network relations, interconnectedness and financial imbalances have become the norm. When struggling banks were forced to write down goodwill assets in their balance sheets this also triggered a write-down in shareholder equity, threatening the capital adequacy capacity of banks to maintain lending and sustain GDP growth trajectories.<sup>2</sup> The reaction of regulatory authorities has been to try and strengthen global banking business balance sheets (with additional reserves and equity injections) to reduce ‘official’ exposure to the banking sector, but this may further curtail lending capacity.

New Basle III capital adequacy will reduce lending capacity going forward by as much as 4–5 per cent.

(*IMF, 2011: 3*)

In normal times and particularly in boom periods, the supply of global liquidity will be largely determined by international banks (either directly or